Search the Newsreel

Eton Pharmaceuticals (ETON) Gains On Rare Disease Momentum, Is It Still Undervalued?

Eton Pharmaceuticals (ETON) saw its stock climb 13.8% recently, contributing to a 33% 30-day return and a 165.68% year-to-date return, driven by its rare disease portfolio. While a fair value analysis suggests the stock is 5.4% undervalued at $43.20 compared to a $45.67 target, …

Eton Pharmaceuticals (ETON) Moves 13.8% Higher: Will This Strength Last?

Eton Pharmaceuticals (ETON) saw its shares jump 13.8% due to investor confidence in its growth prospects, driven by strong commercial momentum from existing products and a promising late-stage pipeline. The company is expected to report significant quarterly earnings and revenue growth. However, Zacks maintains …

Opaleye management sells $1.06m in Eton Pharmaceuticals stock

Opaleye Management Inc., a 10% owner of Eton Pharmaceuticals (NASDAQ:ETON), sold 28,315 shares of the company's common stock for over $1 million on July 14, 2026. Despite the sale, Eton shares have surged more than 200% in the past year and are trading near …

ETON Surges As Canaccord Sets Aggressive $60 Price Target

Eton Pharmaceuticals Inc. (ETON) stock surged by 13.61% after Canaccord Genuity initiated coverage with a "Buy" rating and an aggressive $60 price target, significantly higher than the previous analyst mean. This positive outlook is primarily driven by Eton's focus on ultra-rare pediatric diseases and …

Eton Pharmaceuticals, Inc. 4/A — Insider Transaction

The article reports an insider transaction (Form 4/A) for Eton Pharmaceuticals, Inc. filed on July 17, 2026. This filing is available for viewing on SEC.gov. The platform MLQ.ai provides this research, along with other data on companies, infrastructure, and frontier tech.

Eton Pharmaceuticals (ETON) Stock Looks Overvalued Even After Recent Wins

Despite a significant 13x return over the past three years and recent FDA approval, Eton Pharmaceuticals (ETON) appears overvalued according to Simply Wall St's analysis. The stock trades at a Price/Sales ratio of 13.3x, significantly higher than the industry average of 6.2x, suggesting that …

Form 4 Eton Pharmaceuticals Inc For: 17 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Eton Pharmaceuticals Inc. dated July 17. The brief piece includes the company's stock symbol (ETON) and its performance, showing a 13.79% increase. It serves as a standard financial news alert regarding insider transactions.

ETON Stock Pops As Canaccord Genuity Targets $60

Eton Pharmaceuticals (ETON) stock has risen by 13.61% after Canaccord Genuity initiated coverage with a Buy rating and a $60 price target. This analyst coverage, released on July 16, 2026, has led to a significant surge in trading volume and price action. The company …

Precision Trading with Princeton Bancorp Inc Com (BPRN) Risk Zones

This article provides a precision trading analysis for Princeton Bancorp Inc Com (BPRN), highlighting near-term strong sentiment potentially leading to a long-term positive bias. It outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones for …

Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Up 5.3% - Should You Buy?

Eton Pharmaceuticals stock hits all-time high at 38.76 USD

Eton Pharmaceuticals (ETON) stock has reached an all-time high of $38.76, marking a 175.48% increase over the past year, with a market capitalization of $1.05 billion and nearly 80% revenue growth. While the company exceeded Q1 2026 revenue forecasts, its EPS significantly missed expectations. …

ETON PHARMACEUTICALS INC : CANACCORD GENUITY INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $60

Canaccord Genuity has initiated coverage on Eton Pharmaceuticals Inc. (ETON.O) with a "Buy" rating. The firm has set a target price of $60 for the pharmaceutical company's stock. This indicates a positive outlook on Eton Pharmaceuticals' future performance by Canaccord Genuity.

Eton Pharmaceuticals (ETON) holder Opaleye reports July stock sales

Opaleye Management Inc., a more-than-10% holder of Eton Pharmaceuticals (ETON), reported open-market sales of 28,315 shares of common stock on July 14, 2026. The sales were executed at a weighted average price of $37.5431 per share through a separately managed account and Opaleye, L.P., …

Frontier tech research, news & data

This article provides an update on Eton Pharmaceuticals, Inc. regarding an insider transaction filed on July 16, 2026. It also mentions a "Power Delivery Gap Report" available from MLQ.ai, which analyzes the US grid's capacity for delivering renewable and natural gas power.

BPRN Q2'26 Earnings: revenue estimate is 21.84M USD

Princeton Bancorp, Inc. (BPRN) is scheduled to release its Q2'26 earnings on July 23. Analysts estimate the company will report revenue of $21.84 million and earnings per share (EPS) of $0.88 for the quarter. This article provides a historical overview of BPRN's revenue and …

Princeton Bancorp (BPRN) to Release Quarterly Earnings on Thursday

Princeton Bancorp (BPRN) is set to release its Q2 2026 earnings before market open on Thursday, July 23rd, with analysts forecasting $0.90 EPS and $21.84 million in revenue. The company previously exceeded Q1 expectations and its stock is near a 52-week high, offering a …

Heeton Holdings Limited's (SGX:5DP) largest shareholders are private companies with 51% ownership, insiders own 30%

BOGAZICI-BETON-SANAYI, BOBET Tarihsel Veriler